noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Nielsen Holdings Ltd.

Nielsen helps New Zealand brands expand internationally with greater[...]
Arizona Department of Transportation

ADOT urges motorists to stay alert during Work Zone Awareness Week
GE Vernova Inc.

GE Vernova Foundation Announces Bold, Future-Focused Engineers of[...]

Healthcare

Pappas Capital LLC

04/02/2020 | Press release | Archived content

Curzion Pharmaceuticals Acquired by Horizon Therapeutics

News | 04. 02. 2020

Curzion Pharmaceuticals

DUBLIN -- April 2, 2020 -- Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has acquired Curzion Pharmaceuticals, Inc., a privately held development-stage biopharma company, and its development-stage oral selective lysophosphatidic acid 1 receptor (LPAR₁) antagonist, CZN001 (renamed HZN-825). Under terms of the agreement, Horizon acquired Curzion for a $45 million upfront cash payment with additional payments contingent on the achievement of development and regulatory milestones. CZN001 was originally discovered and developed by Sanofi, which is eligible to receive contingent payments upon the achievement of development and commercialization milestones and royalties based on revenue thresholds.

Pappas Capital LLC published this content on April 02, 2020, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 09:58 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format